Cullinan Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cullinan Therapeutics (CGEM).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$30Upside to Avg. PT+112.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$35
Sep 25, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$30→$35
Sep 25, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Sep 14, 2026	BTIG	Julian Harrison	PT Raise	Buy	$39→$40
Aug 17, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$30
Aug 13, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$39→$42
Jul 29, 2026	BTIG	Julian Harrison	PT Raise	Buy	$38→$39
Jun 11, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$37
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$30
May 19, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
May 8, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$36→$37
May 4, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
Apr 28, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
Apr 28, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$27→$30
Mar 11, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$34→$36
Feb 17, 2026	Citigroup	Samantha Semenkow	Initiate	Buy	$33
Feb 2, 2026	Guggenheim	Brad Canino	Initiate	Buy	$30
Jan 8, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$26→$27
Dec 9, 2025	Wedbush	Robert Driscoll	PT Raise	Outperform	$25→$34
Nov 24, 2025	BTIG	Julian Harrison	PT Raise	Buy	$32→$38

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.

Benzinga Newsdesk

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Vandana Singh

Cullinan Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Cullinan Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

PRO
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

PRO
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

People Also Watch

People Also Watch

Cullinan Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Cullinan Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

PROBTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

PROBTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

PROHC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

PRO
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

PRO
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target